Fibroin

Technologies give leg up to archaeological studies on relics unearthed at Sanxingdui Ruins site

Retrieved on: 
Friday, July 28, 2023

Nearly 600 relics unearthed from the renowned Sanxingdui Ruins debuted to the public.

Key Points: 
  • Nearly 600 relics unearthed from the renowned Sanxingdui Ruins debuted to the public.
  • The Sanxingdui Ruins is the largest ruins of the pre-Qin period (pre-221 BC) featuring the longest duration and the most relics unearthed in southwest China.
  • Over recent years, a number of advanced technologies in multiple disciplines have been employed in archaeological excavations at the Sanxingdui Ruins site, which innovated the research models of major archaeological projects and built open platforms for interdisciplinary cooperation.
  • The 2021 excavation of the Sanxingdui Ruins site just amazed the public with its tech-ish transparent archaeological cabins and archaeologists in "protective suits."

Galderma Announces Exclusive Agreement With Sofregen to Develop the Next Generation of Biostimulator Fillers Using Silk-Based Technology

Retrieved on: 
Thursday, September 23, 2021

This collaboration will further expand Galdermas capabilities built on decades of science-based aesthetics innovation and a unique heritage in biostimulator and hyaluronic acid (HA) fillers.

Key Points: 
  • This collaboration will further expand Galdermas capabilities built on decades of science-based aesthetics innovation and a unique heritage in biostimulator and hyaluronic acid (HA) fillers.
  • At Galderma, were committed to advancing dermatology through constant innovation and joining forces with other industry pioneers.
  • This agreement highlights Sofregens dedication to advancing the science of silk and will accelerate our ability to develop the next generation of biostimulator fillers with a recognized leader in this space.
  • Galderma will also have an exclusive option to acquire Sofregens Silk Voice as well as assets associated with its aesthetics business.

Kraig Biocraft Laboratories Expands Intellectual Property Portfolio

Retrieved on: 
Thursday, August 5, 2021

Kraig Labs developed this new system to address the limits on size and complexity of protein synthesis available from the worlds leading recombinant gene manufacturers.

Key Points: 
  • Kraig Labs developed this new system to address the limits on size and complexity of protein synthesis available from the worlds leading recombinant gene manufacturers.
  • The Company filed both of these patent applications under the World Intellectual Property Organization (WIPO) Patent Cooperation Treaty (PCT) process as well as filing utility patents in the United States of America.
  • The portfolio of IP that our team is building, together with the resulting silk technologies it has produced, leaves me very optimistic for the future of Kraig Labs, our spider silk technologies, and beyond.
  • To view the most recent news from Kraig Labs and/or to sign up for Company alerts, please go to www.KraigLabs.com/news
    Kraig Biocraft Laboratories, Inc. ( www.KraigLabs.com ), a reporting biotechnology company is the leading developer of genetically engineered spider silk based fiber technologies.